Busulfan Sample Collection Study
Start Date
2/8/2024
Completion Date
4/30/2027
Summary
Busulfan (Busulfex®) is an alkylating drug used as a conditioning regimen prior to allogeneic hematopoietic stem cell transplantation. Busulfan has wide inter- and intra-patient pharmacokinetic variability resulting in variable exposure leading to increased risk of toxicities or sub-optimal treatment outcomes. Therapeutic drug monitoring of busulfan using patient plasma samples would benefit clinicians by providing the ability to personalize the dose to achieve a target busulfan exposure.
Detailed Description
This protocol is sponsored by Saladax Biomedical, Inc (SBI). The protocol involves the use of sodium heparin plasma sample collected from human subjects receiving intravenous busulfan treatment for the use in the development of a diagnostic test for this drug. A subset of 10 enrolled subject samples will be tested on site using an automated immunoassay MyCareTM Oncology Busulfan Assay Kit manufactured by SBI.
Eligibility Criteria
Age Range: No minimum to No maximum
Interventions
MyCare Oncology Busulfan Assay Kit
Conditions
Locations
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Chicago, Illinois 60611
United States
Rutgers Cancer Institute
New Brunswick, New Jersey 08903
United States
The University of Texas MD Anderson Cancer Center
Houston, Texas 77030
United States